Logo

PharmaShots Weekly Snapshots (August 02 - 06, 2021)

Share this

PharmaShots Weekly Snapshots (August 02 - 06, 2021)

Medtronic to Acquire Intersect ENT for ~$1.1B

Published: Aug 6, 2021 | Tags: Medtronic, Intersect ENT, ~$1.1B

Kite Signs a License Agreement with Appia to Develop Allogeneic Cell Therapies for the Treatment of Cancer

Published: Aug 6, 2021 | Tags: Kite, Appia, Allogeneic Cell Therapies, Cancer

Polpharma & Bioeq Report BLA Submission to the US FDA for FYB201 (biosimilar, ranibizumab)

Published: Aug 6, 2021 | Tags: Polpharma, Bioeq, BLA, FDA, FYB201, biosimilar, ranibizumab

Takeda Publishes the Results of Takhzyro (lanadelumab) in P-III HELP Study for the Prevention of Hereditary Angioedema Attacks in the Journal Allergy

Published: Aug 6, 2021 | Tags: Takeda, Takhzyro, lanadelumab, P-III, HELP OLE Study, Hereditary Angioedema Attacks, Allergy

AstraZeneca Signs an Exclusive License Agreement with Sierra for AZD5153 to Treat Myelofibrosis

Published: Aug 6, 2021 | Tags: Sierra, AstraZeneca, AZD5153, Myelofibrosis

Bayer to Acquire Vividion for ~$2B

Published: Aug 6, 2021 | Tags: Bayer, Vividion, Drug Discovery Platform, ~$2B

Merck's Keytruda (pembrolizumab) Receives the US FDA's Priority Review for the Adjuvant Treatment of Stage II

Published: Aug 5, 2021 | Tags: Merck, Keytruda, pembrolizumab, P-III, KEYNOTE-716 Trial, Stage II, Resected High-Risk Melanoma

Regeneron and Sanofi Stop P-III EMPOWER-Lung 3 Trial Early Due to Improvement in OS for 1L Treatment of NSCLC

Published: Aug 5, 2021 | Tags: Regeneron, Sanofi, P-III, EMPOWER-Lung 3 Trial, Libtayo, Platinum-Doublet CT, NSCLC

Regeneron Publishes the Results of REGEN-COV (casirivimab and imdevimab) in P-III Trial to Prevent COVID-19 at NEJM

Published: Aug 5, 2021 | Tags: Regeneron, REGEN-COV, casirivimab, imdevimab, P-III, Trial, COVID 19, NEJM

Pfizer Reports Results of Ritlecitinib in P-IIb/III Trial for the Treatment of Alopecia Areata

Published: Aug 5, 2021 | Tags: Pfizer, Ritlecitinib, P-IIb/III, Trial, Alopecia Areata

Schrödinger Signs a R&D Collaboration with Zai Lab for Oncology Program Targeting DNA Damage Response

Published: Aug 5, 2021 | Tags: Schrödinger, Zai Lab, Oncology program, DNA damage response

F-star Collaborates with MSD to Evaluate FS120 + Keytruda for the Treatment of Cancer

Published: Aug 5, 2021 | Tags: F-star, MSD, FS120, Keytruda, Cancer

BeyondSpring Reports Results of Plinabulin + Docetaxel in P-III DUBLIN-3 Trial for 2L and 3L Treatment of NSCLC with EGFR Wild Type

Published: Aug 4, 2021 | Tags: BeyondSpring, Plinabulin, Docetaxel, P-III, DUBLIN-3 Trial, NSCLC, EGFR Wild Type

Outlook Reports Results of ONS-5010 / Lytenava (bevacizumab-vikg) in P-III NORSE TWO Trial for the Treatment of Wet AMD

Published: Aug 4, 2021 | Tags: Outlook, ONS-5010, Lytenava, bevacizumab-vikg, P-III, NORSE TWO Trial, Wet AMD

Celltrion to Supply Herzuma (biosimilar, trastuzumab) and Truxima (biosimilar, rituximab) in Brazil

Published: Aug 4, 2021 | Tags: Celltrion, Herzuma, biosimilar, trastuzumab, Truxima, rituximab, Brazil

Tachyon Collaborates with AbCellera to Develop Novel Antibody Therapies Targeting TGF-ß Superfamily Member for Cancer

Published: Aug 4, 2021 | Tags: Tachyon, AbCellera, Novel Antibody Therapeutic, TGF-ß Superfamily Member, Cancer

Bayer Reports Results of Eliapixant (BAY1817080) in P-IIb Study for the Treatment of Refractory Chronic Cough

Published: Aug 4, 2021 | Tags: Bayer, Eliapixant, BAY1817080, P-IIb, Study, Refractory Chronic Cough

Marinus Signs an Agreement with Orion for the Commercialization of Ganaxolone in EU

Published: Aug 4, 2021 | Tags: Marinus, Orion, Ganaxolone, EU

Lilly and Incyte Report Results of Baricitinib in P-III COV-BARRIER Study for Patients with COVID-19 Receiving Invasive Mechanical Ventilation

Published: Aug 3, 2021 | Tags: Lilly, Incyte, Baricitinib, P-III, COV-BARRIER Study, COVID 19

UCB's Bimekizumab Receives NICE Recommendation for the Fast-Track Appraisal to Treat Severe Plaque Psoriasis

Published: Aug 3, 2021 | Tags: UCB, Bimekizumab, NICE Recommendation, Severe Plaque Psoriasis

Novartis Lifts Partial Clinical Trial Hold on OAV-101 Clinical Program to Treat SMA

Published: Aug 3, 2021 | Tags: Novartis, Partial, Clinical Trial Hold, OAV-101, SMA

Roche Reports the US FDA's Acceptance of BLA and Priority Review of Tecentriq (atezolizumab) as an Adjuvant Treatment for NSCLC

Published: Aug 3, 2021 | Tags: Roche, US, FDA, BLA, Priority Review, Tecentriq, atezolizumab, NSCLC

Sanofi to Acquire Translate Bio for ~$3.2B

Published: Aug 3, 2021 | Tags: Sanofi, Translate Bio, ~$3.2B

Abbott Launches Jot Dx Insertable Cardiac Monitor to Detect Abnormal Heart Rhythms in US

Published: Aug 3, 2021 | Tags: Abbott, Jot Dx, Insertable Cardiac Monitor, Abnormal Heart Rhythms, US

Regeneron Reports the EUA Expansion for REGEN-COV (casirivimab and imdevimab) to Treat COVID 19

Published: Aug 2, 2021 | Tags: Regeneron, EUA, REGEN-COV, casirivimab, imdevimab, COVID 19

Ipsen Signs an Exclusive Collaboration with Exicure to Develop SNA-Based Therapeutics for Rare Neurodegenerative Disorders

Published: Aug 2, 2021 | Tags: Ipsen, Exicure, SNA-Based Therapeutics, Rare Neurodegenerative Disorders

Janssen's Uptravi (selexipag) Receives the US FDA's Approval for IV Use in Adults with Pulmonary Arterial Hypertension

Published: Aug 2, 2021 | Tags: Janssen, UPTRAVI, selexipag, US, FDA, Approval, Pulmonary Arterial Hypertension

AstraZeneca's Saphnelo (anifrolumab-fnia) Receives the US FDA's Approval for the Treatment of Moderate to Severe Systemic Lupus Erythematosus

Published: Aug 2, 2021 | Tags: AstraZeneca, Saphnelo, anifrolumab-fnia, US, FDA, Approval, Systemic Lupus Erythematosus

Takeda and Frazier Collaborate to Launch HilleVax (biopharma company) for the Development of Norovirus Vaccine

Published: Aug 2, 2021 | Tags: Takeda, Frazier, HilleVax, biopharma company, HIL-214

Astellas Signs a License Agreement with Minovia for Novel Mitochondrial Cell Therapy Programs

Published: Aug 2, 2021 | Tags: Astellas, Minovia, Mitochondrial Cell Therapy Programs

Related Post: PharmaShots Weekly Snapshots (July 26 - 30, 2021)


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions